97 related articles for article (PubMed ID: 16152584)
1. Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancers.
Iijima H; Tomizawa Y; Iwasaki Y; Sato K; Sunaga N; Dobashi K; Saito R; Nakajima T; Minna JD; Mori M
Int J Cancer; 2006 Feb; 118(4):797-801. PubMed ID: 16152584
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma.
Yi HM; Li H; Peng D; Zhang HJ; Wang L; Zhao M; Yao KT; Ren CP
Oncol Res; 2006; 16(6):261-72. PubMed ID: 17476971
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
5. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
[TBL] [Abstract][Full Text] [Related]
6. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
7. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer.
Wu W; Kemp BL; Proctor ML; Gazdar AF; Minna JD; Hong WK; Mao L
Cancer Res; 1999 Apr; 59(8):1846-51. PubMed ID: 10213490
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer.
Virmani A; Rathi A; Sugio K; Sathyanarayana UG; Toyooka S; Kischel FC; Tonk V; Padar A; Takahashi T; Roth JA; Euhus DM; Minna JD; Gazdar AF
Int J Cancer; 2003 Aug; 106(2):198-204. PubMed ID: 12800194
[TBL] [Abstract][Full Text] [Related]
10. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
Lerman MI; Minna JD
Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
[TBL] [Abstract][Full Text] [Related]
11. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer.
Okamoto A; Hussain SP; Hagiwara K; Spillare EA; Rusin MR; Demetrick DJ; Serrano M; Hannon GJ; Shiseki M; Zariwala M
Cancer Res; 1995 Apr; 55(7):1448-51. PubMed ID: 7882351
[TBL] [Abstract][Full Text] [Related]
13. Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line.
Nishioka M; Kohno T; Takahashi M; Niki T; Yamada T; Sone S; Yokota J
Oncogene; 2000 Dec; 19(54):6251-60. PubMed ID: 11175339
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of laminin-5-encoding genes in lung cancers.
Sathyanarayana UG; Toyooka S; Padar A; Takahashi T; Brambilla E; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Jul; 9(7):2665-72. PubMed ID: 12855645
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures.
Toyooka S; Fukuyama Y; Wistuba II; Tockman MS; Minna JD; Gazdar AF
Clin Cancer Res; 2002 Jul; 8(7):2292-7. PubMed ID: 12114433
[TBL] [Abstract][Full Text] [Related]
16. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers.
Osada H; Tatematsu Y; Yatabe Y; Nakagawa T; Konishi H; Harano T; Tezel E; Takada M; Takahashi T
Oncogene; 2002 Apr; 21(15):2418-24. PubMed ID: 11948426
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines.
Yanagisawa K; Kondo M; Osada H; Uchida K; Takagi K; Masuda A; Takahashi T; Takahashi T
Cancer Res; 1996 Dec; 56(24):5579-82. PubMed ID: 8971157
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
19. Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines.
Zhang H; Feng X; Liu W; Jiang X; Shan W; Huang C; Yi H; Zhu B; Zhou W; Wang L; Liu C; Zhang L; Jia W; Huang W; Li G; Shi J; Wanggou S; Yao K; Ren C
J Cell Biochem; 2011 Jul; 112(7):1832-43. PubMed ID: 21400573
[TBL] [Abstract][Full Text] [Related]
20. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Williams NN; Kaiser LR; Croce CM
Cancer Res; 2003 Jun; 63(12):3352-5. PubMed ID: 12810670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
